The benefits of antioxidants or DHA/EPA supplementation for CF , although observed in some studies , are not consistent enough to recommend routine use of these supplements .
Antioxidant micronutrients and essential fatty acids supplementation intake appears to have a protective effect in some diseases such as cardiovascular disease , cancer , and asthma .
The aim of this study was to perform a systematic review to evaluate the effects of these nutrients on nutritional and clinical outcomes of patients with cystic fibrosis ( CF ) .
This is a systematic review of r and omized clinical trials ( RCTs ) in CF .
The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis.
The substitution of omega-3 ( n-3 ) fatty acids for omega-6 ( n-6 ) fatty acids generates eicosanoids with diminished inflammatory effects . As the lungs of patients with cystic fibrosis ( CF ) are in a state of chronic inflammation in which increased amounts of eicosanoids are found , n-3 supplementation may reduce this level of inflammation and result in clinical improvement . The absorption and clinical effects of n-3 vs. n-6 fatty acids in CF were measured in a prospect i ve , r and omized , double-blind , crossover study in which 14 patients with CF ( age : 6 - 16 years , mean 10.5 years ; baseline Shwachman-Brasfield scores : 41 - 88 , mean 76.7 ) received 6 weeks of n-3 ethyl ester concentrate from menhaden oil ( 100 - 131 mg/kg/day , mean 112.8 ) or n-6 fatty acids from safflower oil ( 102 - 132 mg/kg/day , mean 113.3 ) , followed by a washout period of 6 weeks , and then 6 weeks of the other supplement . Analysis by gas chromatography showed that n-3 supplementation result ed in increased eicosapentaenoic acid ( 20:5n-3 ) in platelet phospholipids , from 0.14 to 2.16 % , P < 0.05 and in increased docosahexaenoic acid ( 22:6n-3 ) , from 1.33 to 3.72 % , P < 0.05 . Clinical effects were evaluated at weeks 0 , 6 , 12 , and 18 , and analyzed for differences among the n-3 , n-6 , and washout periods . No adverse effects were reported or observed . No statistically significant differences were found ( ANOVA , P > 0.05 ) in Shwachman-Brasfield scores , sweat test , weight change , or forced expiratory volume and flow ( FEV1 , FEF25 - 75 % , and FVC ) percentiles . Tumor necrosis factor was not measurable in any serum sample . Serum leukotriene B4 ( LTB4 ) levels were significantly reduced by n-3 fatty acids , mean reduction ( -177 pg/mL ) compared to n-6 fatty acids ( + 63 pg/mL ) P < 0.05 . These results show that both n-3 fatty acids are absorbed and incorporated into platelet phospholipids in patients with CF and reduced serum LTB4 . No significant clinical differences or adverse effects were found
The benefits of antioxidants or DHA/EPA supplementation for CF , although observed in some studies , are not consistent enough to recommend routine use of these supplements .
Antioxidant micronutrients and essential fatty acids supplementation intake appears to have a protective effect in some diseases such as cardiovascular disease , cancer , and asthma .
The aim of this study was to perform a systematic review to evaluate the effects of these nutrients on nutritional and clinical outcomes of patients with cystic fibrosis ( CF ) .
This is a systematic review of r and omized clinical trials ( RCTs ) in CF .